β-defensin 34 Inhibitors
β-defensin 34 inhibitors are chemical agents designed to modulate the activity of β-defensin 34, a specific member of the defensin family of peptides. Defensins are small, cysteine-rich proteins that play a crucial role in immune system processes, particularly within epithelial tissues. β-defensin 34 is part of the broader β-defensin group, characterized by their β-sheet structure stabilized by disulfide bonds. The inhibitors targeting β-defensin 34 interact at the molecular level by disrupting the peptide's function, which may involve binding directly to the active sites or altering the structural integrity of the molecule, thereby interfering with its interactions and functions in a cellular environment. These inhibitors are of significant interest due to their ability to affect specific biochemical pathways associated with β-defensin 34 activity.
The design of β-defensin 34 inhibitors involves a deep understanding of the peptide's structure, particularly the configuration of disulfide bonds that maintain its stability and function. Molecular modeling, combined with techniques such as X-ray crystallography or nuclear magnetic resonance (NMR) spectroscopy, can help elucidate the precise conformational changes that occur when an inhibitor binds to β-defensin 34. Inhibitors can be small molecules, peptides, or larger biomolecules specifically tailored to interfere with the unique structural features of β-defensin 34. A key focus in the development of these inhibitors is optimizing their specificity to avoid off-target effects on other defensins or similar proteins, which requires fine-tuning the molecular characteristics such as size, charge, and hydrophobicity to align with the target peptide's binding sites. The study of these inhibitors extends into understanding the downstream effects on the systems and networks where β-defensin 34 operates.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Olaparib | 763113-22-0 | sc-302017 sc-302017A sc-302017B | 250 mg 500 mg 1 g | $210.00 $305.00 $495.00 | 10 | |
PARP inhibitor disrupting DNA repair. Olaparib indirectly inhibits β-defensin 34 by interfering with the DNA damage response pathway, impacting the regulation of β-defensin 34 transcription under conditions of cellular stress. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
PI3K inhibitor disrupting the PI3K/AKT pathway. LY294002 indirectly hampers β-defensin 34, as PI3K/AKT signaling is implicated in the regulation of β-defensin 34 transcription by modulating specific transcription factors. | ||||||
Ruxolitinib | 941678-49-5 | sc-364729 sc-364729A sc-364729A-CW | 5 mg 25 mg 25 mg | $251.00 $500.00 $547.00 | 16 | |
JAK inhibitor targeting JAK-STAT signaling. Ruxolitinib indirectly suppresses β-defensin 34, as the JAK-STAT pathway regulates the transcription of β-defensin 34 by activating STAT proteins. | ||||||
Cyclosporin A | 59865-13-3 | sc-3503 sc-3503-CW sc-3503A sc-3503B sc-3503C sc-3503D | 100 mg 100 mg 500 mg 10 g 25 g 100 g | $63.00 $92.00 $250.00 $485.00 $1035.00 $2141.00 | 69 | |
Calcineurin inhibitor affecting the NFAT pathway. Cyclosporin A indirectly inhibits β-defensin 34 by blocking NFAT activation, a key regulator of β-defensin 34 transcription in response to various stimuli. | ||||||
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $114.00 $166.00 $947.00 | 19 | |
MEK inhibitor influencing the MAPK/ERK pathway. Trametinib indirectly influences β-defensin 34 expression by disrupting the MAPK/ERK pathway, which modulates β-defensin 34 transcription through specific downstream effectors. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
JNK inhibitor affecting the AP-1 pathway. SP600125 indirectly hinders β-defensin 34, as the AP-1 transcription factor, downstream of JNK, is involved in the transcriptional regulation of β-defensin 34. | ||||||
Suberoylanilide Hydroxamic Acid | 149647-78-9 | sc-220139 sc-220139A | 100 mg 500 mg | $133.00 $275.00 | 37 | |
HDAC inhibitor modulating chromatin structure. Vorinostat indirectly suppresses β-defensin 34 by altering histone acetylation, influencing the accessibility of the β-defensin 34 gene for transcription. | ||||||
Quinomycin A | 512-64-1 | sc-202306 | 1 mg | $166.00 | 4 | |
HIF-1α inhibitor affecting the hypoxia pathway. Echinomycin indirectly suppresses β-defensin 34, as HIF-1α enhances β-defensin 34 transcription under hypoxic conditions, and inhibiting HIF-1α disrupts this regulatory mechanism. | ||||||
Eprosartan | 133040-01-4 | sc-207631 | 10 mg | $169.00 | 1 | |
TLR4 inhibitor affecting the TLR4 signaling pathway. CLI-095 indirectly hampers β-defensin 34, as TLR4 activation is known to upregulate β-defensin 34 expression through NF-κB and AP-1 signaling cascades. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
mTOR inhibitor influencing the mTORC1 pathway. Rapamycin indirectly inhibits β-defensin 34 by modulating mTORC1 signaling, which is implicated in the regulation of β-defensin 34 through control of translation initiation. | ||||||